Drug Profile


Alternative Names: Cancer vaccine - Scancell; ImmunoBody melanoma vaccine - Scancell; Melanoma vaccine TRP2 gp100 - Scancell; SCIB-1

Latest Information Update: 13 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scancell
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes - Malignant melanoma

Highest Development Phases

  • Phase I/II Malignant melanoma

Most Recent Events

  • 13 Sep 2017 Scancell announces intention to submit an IND application with the US FDA for Malignant melanoma in early 2018
  • 11 Jul 2017 Updated efficacy data from a phase I/II trial in Malignant melanoma released by Scancell
  • 26 Jun 2017 Scancell has patent protection for DNA ImmunoBody® platform technology in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top